窑Clinical Research窑
Chronic myeloid leukemia (CML) is a pluripotential hematopoietic stem cellderived malignant myeloproliferative disease with characteristic cytogenetics (Ph chromosome) and molecular biology (expression of BCR/ABL fusion gene). Blast crisis is the advanced stage of CML when treatment efficacy is generally poor. Allogeneic hematopoietic stem cell transplantation (alloHSCT) and treatment with tyrosine kinase inhibitor provide a chance of complete molecular response for CML patients, that is, the level of BCR/ABL gene is reduced to an undetectable level. Although the emergence of imatinib has pioneered on the targeting treatment for CML, alloHSCT is still the only curative method for CML for the time being 1 . However, recurrence after transplantation is one of the major influential factors for the longterm survival in CML patients. Early determination on whether the patients need intervention and dynamic monitoring minimal residual disease (MRD) (BCR/ABL gene) after alloHSCT is helpful in improving the overall efficacy and safety of HSCT, predicting recurrence and facilitating the implementation of intervention.
Monitoring methods for MRD include fluorescence in situ hybridization (FISH) and realtime quantitative reverse transcription PCR (RQPCR). FISH was once used as a diagnostic method for CML and a followup and monitoring tool on MRD. RQPCR, as a new technique for monitoring MRD in recent years, analyzes BCRABL gene quantitatively at mRNA level. Quantitative detection of the level of BCRABL gene was performed in 31 CML patients who had received alloHSCT treatment in our hospital. Herein, we summarized and analyzed the role of FISH and RQPCR as clinical monitoring tools on MRD in CML patients.
the Nanfang Hospital, Southern Medical University between May 2004 and May 2009 were selected. Of these patients, 26 were male and five female, with a median age of 35 years (age range 1241 years). All these patients were confirmed and staged by cytomorphology, cell histochemistry, cytogenetics and molecular genetics, and underwent alloHSCT in Nanfang Hospital within one year after being diagnosed. Informed consent about alloHSCT was obtained from all the patients. Before transplantation, 22 patients were at chronic phase and nine at blast crisis or acceleration phase. Among them, 24 patients were treated with hydroxyurea and the other seven with imatinib. After the transplantation, FISH and RQPCR were performed to detect BCRABL fusion gene at varied time points. Followup time after transplantation ranged from 3 to 48 months. A total of 159 bone marrow samples were collected at different time points before and after the transplantation.
A dualcolor dualfusion DNA probe provided by Vysis was used for the detection. According to the FISH operation procedures for interphase cells in the hematology laboratory of Nanfang Hospital, the samples were treated, denatured, hybridized and eluted
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. Hybridization signals were observed under fluorescent microscope Nikon E600 with a tricolor filter (DAPI/TRITC/ FITC); red signal indicated BCR, green signal indicated ABL, while yellow signal indicated BCRABL fusion. In the interphasic nucleus of a normal cell, four hybridization signals could be seen, including two red and two green signals, and red signals were well separated from green ones, while in interphasic nucleus with BCRABL expression, one red and one green hybridization signals and one yellow fusion signal could be found. Images were taken by a highresolution CCD (by COHU) and analyzed by a fluorescent image analyzing system (by PSI, England). A total of 1000 cells were counted for each sample. A BCRABL positive cell percentage of 臆 3% was considered as a background signal 3 .
Extracted bone marrow was anticoagulated with EDTA and was used for extraction of monocytes with Ficoll separation buffer. Trizol reagent was used to extract total RNA, which was then retrotranscripted into cDNA. Realtime quantitative amplification was performed on the cDNA in a fluorescent quantitative PCR apparatus MJ Opticon2 (BioRad, US). Reaction system (25 滋 L) included 300 nmol/L upstream and downstream primers, respectively, 200 nmol/L man probe, 12.5 滋 L of 2 伊 man PCR mixed buffer (ABI, US) and 2 滋 L of template cDNA. Sequences of primers and probes are shown in Table 1 . PCR reactions were catalyzed by one cycle of 5 min at 95益 and 45 cycles of 15 s at 95益 and 1 min at 58益. ABL gene was used as an internal control. Sequences of primer and probe were designed and standard curve was generated according to the routine procedures in our laboratory 4 . A standard curve with a correlation coefficient (r) of 逸 0.99 was considered robust. The standard curve for the RQPCR detection was based on a BCRABL positive plasmid with P210 breakpoint sequence (standard sample). The positive plasmid was quantitatively measured and diluted at a ratio of 1 : 10, and underwent quantitative amplification in the PCR reaction system as described above. In this study, we used a relatively quantitative method with standard curve. Using ABL gene as internal control, the standard curve was generated automatically based on the results from the standard sample. The absolute copy numbers of BCR/ABL fusion gene and internal control gene ABL were then measured, respectively. The ratio of fusion gene to internal control gene (copy number of BCRABL / copy number of ABL × 100% ) was considered as the RQPCR result for the patients. Detection results of different patients were calculated using the standard curve.
All the data were processed by SPSS13.0 software. FISH results were shown as the percentage of BCRABLpositive cells/all the cells counted, and RQPCR results as the ratio of BCRABL to ABL. Measurement data were presented as mean ± standard deviation (SD). Results of FISH and RQPCR detections before transplantation were used as controls. All the detection results from FISH and RQPCR after transplantation were compared with the results before transplantation. The differences between the results at various time points after transplantation and those of the controls were analyzed using test. Test level was set at 琢 = 0.05.
In FISH detection among 31 CML patients, the mean percentage of BCRABL fusion genepositive cells was (96.2 依 3.8)% (Figure 1 ). The standard curve for RQPCR detection of BCRABL gene is shown in Figure 2 . The mean ratio of BCRABL to ABL was 0.74 依 0.11.
In one patient, the percentage of BCRABL genepositive cells in FISH detection at three months after transplantation was 10.9%, and the ratio of BCRABL to ABL mRNA by RQPCR was 0.15; at six months after transplantation, the percentage of positive cells in FISH detection was 54% , and ratio of BCRABL to ABL by RQPCR was 0.31. At this time point, oral imatinib was given immediately at the dosage of 600 mg, qd. Currently, the patient has maintained in complete hematological remission. Another patient had complete hematological remission at six months after transplantation, but FISH detection revealed a positive cell percentage of 13% and RQPCR detection revealed a ratio of BCRABL to ABL of 0.18, which were far from complete molecular remission. At 12 months after transplantation, FISH detection revealed that positive cell percentage was 65% , while ratio of BCRABL to ABL in RQPCR was 0.21. At this time point, imatinib was given at the dosage as described above. The patient has maintained in complete hematological remission.
In the rest of the patients, when comparing the results of FISH and RQPCR detection at various time points after transplantation with those before transplantation, the detection levels (percentage and ratio) were significantly decreased ( < 0.05). At 30 months after transplantation,results from FISH detection were 0, while RQPCR still revealed a detectable expression level of BCRABL/ABL (Table 2) diagnosing CML. During the treatment for CML, it is necessary to conduct a dynamic monitoring on tumor burden, so as to modify treatment scheme and achieve a complete cytogenetic remission (CCR, percentage of Ph + cells is 0) and a complete molecular response (CMR, negative BCRABL fusion gene mRNA) or a major molecular response (MMR, BCRABL mRNA level reduced by 逸 3 logarithmic units). Currently, FISH and RQPCR have become important approaches in diagnosing CML and monitoring MRD 2 .
Cortes
. 5 combined these two methods when detecting 280 patients treated with imatinib and found that results of RQPCR and FISH detections were well consistent in FISHpositive samples. Both methods are quantitative monitoring tools for MRD, with different sensitivity and specificity. In FISH, single strand DNA with fluorescence label (probe) and its complementary DNA (sample on the slide) are annealed and hybridized. FISH reflects relevant gene expression by the sites of fluorescent signals in the chromosome as observed under microscope. A total of 1 000 cells were calculated, and the results were shown as the percentage of positive cells. Dualcolor dualfusion FISH has a lower false positive rate than the dualcolor singlefusion version, and is a favorable tool for the rapid diagnosis in treatmentna魵 ve patients. However, the sensitivity of FISH detection is dependent on the skill proficiency of the lab technicians in scanning a few hundreds of interphase cells. FISH is not sensitive enough as a monitoring tool on MRD. While in RQPCR, fluorescent labels are added to the PCR system. The PCR process is monitored on a realtime basis by the accumulation of fluorescent signals. Finally, unknown template is quantitatively analyzed using a standard curve. In this method, Taq Man probe technique provides an excellent specificity, low false positivity and fine linearity. In the followup of CML patients treated with alloHSCT or imatinib, RQPCR is apparently better than FISH and is currently recognized as the golden standard in monitoring the leukemic residue level 6, 7 . In the CML patients of this study, with the detection results before transplantation as baseline data, the average percentage of BCRABL fusion genepositive cells in FISH detections at various time points was significantly reduced in 31 patients after transplantation ( < 0.05). At 30 months after transplantation, the result of FISH detection was 0. When comparing the BCRABL/ABL ratio in RQPCR detection to the average baseline level before transplantation, the posttransplantation level was decreased by > 2 logarithmic units within 330 months after transplantation and by > 3 logarithmic units at 30 months afterward. Our observation showed that results of RQPCR and FISH detections were well correlated. When FISH was negative, RQPCR could still reveal the changes in BCRABL/ABL ratio, suggesting that RQPCR had a better sensitivity than FISH. When positive results were yielded in consecutive RQPCRs but FISH revealed negative results, the possibility of recurrence was indicated. At this time point, if imatinib was given, FISH detection could turn negative, while RQPCR level might be still decreasing 6, 8 . Therefore, RQPCR was more accurate in detecting the lower level of BCRABL transcript and could be used as a sensitive marker for monitoring MRD.
In conclusion, dynamic monitoring of BCRABL gene on molecular level in CML patients after alloHSCT is useful in the early prediction of susceptibility to recurrence in the patients and in designing intervention, and is thus helpful in improving the overall survival rate after transplantation.
